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Abstract
Atherosclerotic disease of the arteries is a major cause of coronary artery disease, peripheral
vascular disease and stroke. Some patients are however not candidate for the standard treatment
of angioplasty or bypass surgery. Hence there is tremendous enthusiasm for the utilization of
angiogenesis as a therapeutic modality for atherosclerotic arterial disease. This augmentation of
physiological neo-vascularization in cardiovascular disease can be achieved through different
pathways. In this article we are reviewing the Use of Gene therapy, Protein therapy and cellular
therapy.
Introduction
In the 20th century, the number of patients affected by
atherosclerosis increased dramatically. Cardiovascular
disease due to atherosclerosis had become the first cause
of death worldwide as compared to infectious diseases at
the beginning of the century. The natural history of
atherosclerosis can be divided into three stages:
• Stage I: Asymptomatic fatty streak and fibrous plaque
formation.
￿ Stage II: Symptomatic: Formation of fibrous plaque with
medial calcification; enlargement of the fibrous plaque
and thrombus formation; significant homodynamic
occlusion of the vessel and then complete occlusion.
￿ Stage III: Where three major complications are seen:
- Myocardial infarction.
- Brain infarction.
- Gangrene.
Risk factors and disease management
The risk factors for having atherosclerotic disease are age,
hyperlipidemia, smoking, hypertension, physical inactiv-
ity, obesity and hormone status. The conventional man-
agement of atherosclerotic arterial insufficiency can be
divided into three major parts:
￿ Risk factors modification and medical treatment in
order to restore the balance between the oxygen demand
and oxygen supply and prevention of acute thrombotic
episodes, these can be achieved by: Lifestyle modification
(exercise, smoking cessation, weight reduction), and Cho-
lesterol lowering. Another risk factor modification is
Blood pressure management through the following thera-
pies like Aspirin therapy, Beta- blocker, ACE inhibitors.
And the last is through interventional therapy which is
divided into: Surgical: Includes aorto-coronary bypass,
transmyocardial revascularization (TMR) and peripheral
vascular bypass and catheter-based: which include percu-
tanous trans-coronary angioplasty and stenting or coro-
nary atherectomy.
Despite the improvement of these interventions and out-
comes there are many patients that are not suitable candi-
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dates because of their diffuse and severe atherosclerotic
CAD and/or because of the risky nature of the interven-
tion. Hence the idea came of promoting and stimulating
the process of angiogenesis with newly created vessels
which could serve as a biological bypass of the atheroscle-
rotic vessel.
Neovascularization
During the development of the embryo and the physio-
logical repair of any tissue damage, the formation of new
blood vessels plays a major role [1]. Some of this new
blood vessel formation is normal and beneficial as can be
seen in wound healing after trauma, ischemic tissue resto-
ration and in the endometrium during the menstrual
cycle. Abnormal formation of blood vessels however, also
occur and contributes to a number of important disease
processes such as diabetic retinopathy, malignancy, and
diseases like rheumatoid arthritis, systemic lupus ery-
thematosus and in atherosclerotic disease[2-5]. Stimula-
tion of new blood vessel growth must therefore be site
specific and organ specific.
There are three major processes that contribute to the
growth of new blood vessels that are termed globally as
neovascularization:
￿ Vasculogenesis: At the beginning it was thought that
this happens during embryogenesis in which there is a dif-
ferentiation of embryonic mesenchymal cells (such as the
endothelial precursor cells or angioblasts) into endothe-
lial cells and the de novo development of blood vessels
but now it is well known that it contribute to the adult
neovasculirization as well [6]. This process is believed to
be induced by FGF, VEGF and other angiogenic factors or/
and tissue ischemia. This process leads to the develop-
ment of new blood vessels that are formed are composed
mainly of endothelial cells and are referred to as the cap-
illary plexus. The smooth muscle layer that incorporates
in the plexus results from migration and proliferation of
different cell types like pericytes, smooth muscles cells
and fibroblasts [7,8].
￿ Angiogenesis: It is the formation of new blood vessels
by sprouting from pre existing small vessels in adult and
embryonic tissue or by intravascular subdivision process
called intussusception [9,10]. These new blood vessels are
usually lacking developed media. It occurs as the level of
local angiogenic stimuli increases; this will lead to the
activation of the endothelial cells found in pre-existing
vessels, with subsequent vasodilatation, increase permea-
bility and the disruption of the basement membrane
encompassing endothelial cells of the pre-existing capil-
laries via proteolytic degradation. Disturbance of the base-
ment membrane allow the cytoplasmic process to extend
from the activated endothelial cells, directing their migra-
tion and sprouting to the extra vascular space towards the
angiogenic stimuli [11]. The cells elongate and aligned to
form capillary sprouts and then these sprouts will form a
lumen and connect with the neighboring vessels, these
capillaries are very small in size and their contribution to
the actual blood flow with no or little significance to the
ischemic tissue.
￿ Arteriogenesis: It is defined as a rapid proliferation of
pre-existing collateral vessels and these vessels have fully
developed tunica media [9,12]. It is a mature type of neo-
vascularization which can restore perfusion to an
ischemic area.
The occurrence of both angiogenesis and arteriogenesis
has been shown in many animal models and in patients
with coronary artery disease. Tissue ischemia is one of the
key factors that stimulate neovascularization [9].
Folkman has described a series of morphological and bio-
chemical events involved in angiogenesis as, Vasodilata-
tion of parent vessel, degradation of basement membrane,
endothelial migration, endothelial cell proliferation,
lumen formation, loop formation, formation of new
basement membrane, and incorporation of pericytes [13].
Angiogenesis triggering factors
It is a very complex process. Conceptually the major trig-
gers of this process can be simplified into three broad cat-
egories: mechanical, chemical and molecular factors.
1. Mechanical influences
and this can by explained by two factors either through
homodynamic or the shear stress:
￿ Hemodynamic: Augmentation of blood flow during exer-
cise, the hyperthyroid state (Thyrotoxicosis) and adminis-
tration of certain drugs have all been shown to stimulate
vascular sprouting[14-17]. It also has been shown that
large vessels with low flow tend to reduce or obliterate
their endovascular diameter and the lumens of the small
vessels with chronically increased high blood flow tend to
enlarge [18]. Augmentation of blood flow therefore may
both stimulate vascular sprouting and maintain patency
of the newly formed collateral vessels and so providing
blood flow to the ischemic area.
￿ Shear Stress: Shear stress has an important influence on
the development of collaterals in the ischemic tissues.
Shear stress and stretch of the myocardium (i.e. increase
left ventricular end diastolic volume) can lead to up-regu-
lation of adhesion molecules in the endothelium, attrac-
tion of the inflammatory cells and stimulation of the
endothelial cells to produce angiogenic factors[19-22].Journal of Cardiothoracic Surgery 2007, 2:49 http://www.cardiothoracicsurgery.org/content/2/1/49
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2. Chemical influence
this can happen either through hypoxia or through the
production of nitric oxide:
￿ Hypoxia and oxygen tension gradient: Hypoxia stimu-
lates macrophages to release various factors including
platelets derived growth factor and fibroblast growth fac-
tor 1 and 2 [23]. Hypoxia has been shown to upregulate
vascular endothelial growth factor owing both by increas-
ing transcription mediated by hypoxia inducible factor 1
and by increasing the stability of vascular endothelial
growth factor mRNA [24-26]. Hypoxia also increase the
expression of vascular endothelial growth factor recep-
tors(FLK and FLT) this renders the endothelium suscepti-
ble to either the systematic or the paracrine effect of pre-
existing vascular endothelial growth factor [27,28].
￿ Nitric oxide: VEGF is known to induce the release of
Nitric oxide from endothelial cells, and vascular endothe-
lium inducible NO synthase (iNOS) production is ampli-
fied during VEGF- induced angiogenesis [28]. The role of
Nitric Oxide in VEGF induced angiogenesis have been
shown in NOS knocked out mice as well as after NOS
inhibition, both result in reduction of angiogenesis [29-
32]. Nitric Oxide has also a regulatory effect on VEGF pro-
duction.
3. Molecular influences
￿ Effect of glucose on VEGF expression: Hypoglycemia
increases VEGF expression, and after equilibration of the
glucose concentration the level of VEGF return back to
normal [33,34]. This most likely happen when intracellu-
lar CA2+ levels increases in glucose deprived environment
leads to activation of protein kinase C. this process
induces the activation of Angiopoiten -1, leading to an
increase of VEGF expression [35]. Not only hypoglycemia
increases VEGF expression but also hyperglycemia do the
same thing both of which can result an increase in the pro-
duction of VEGF[36,37].
￿  Inflammation: Animal studies have shown that the
presence of inflammatory cells, like macrophages and
neutrophils is sufficient to produce angiogenesis. Follow-
ing myocardial necrosis, the influx of inflammatory cells
including macrophages, monocytes, and platelets results
in the release of cytokines that are capable of stimulating
fibroblast growth factor and vascular endothelial growth
factor expression [38,39]. Vascular endothelial growth
factor by itself can stimulate and recruit other macro-
phages to stimulate inflammation response and further
stimulate angiogenesis.
￿ Angiogenic growth factors: The existence of angiogenic
factors were first observed with the isolation of tumor fac-
tors that generate mitogenic activities in endothelial cells
[40-42]. They are induced by a many varieties of cells and
their functions are development as well as tumor angio-
genesis. Angiogenic growth factors are called so because of
their ability to induce the proliferation of various cells in
vitro, which contribute to the process of angiogenesis in
vivo as shown by studies of animal models. We will
describe briefly couple of these growth factors:
a. Fibroblast growth factor(FGF): The first angiogenic
growth factor to be discovered as a member of a family
currently comprises at least 20 molecules with extensive
mitogenic potentials representing some of the most
potent angiogenic peptide [41-43]. They are produced by
vascular endothelial cell and smooth muscle cells. One
characteristic of the FGF family is the ability to interact
with heparin- like glycosaminoglycan of the extracellular
matrix [44]. The two most widely researched isoforms are
FGF-1 and FGF-2[45-48].
b. Vascular endothelial growth factor (VEGF): Was ini-
tially purified as vascular permeability factor from tumor
cell ascites [49]. It is now known as a multifunctional pep-
tide capable of inducing receptor- mediated endothelial
cell proliferation and angiogenesis both in vivo and in
vitro. It has a crucial role in embryonic vascular develop-
ment and in adult pathophysiology. VEGF is a family
composed of five members and their effect mediated
through three receptors (VEGFR)[50-53].
c. Placenta growth factor: Got its name because of it pre-
dominance in placental tissue. It has little angiogenic
effect in vitro but it seems that both PLGF and VEGF
maybe co expressed in vivo [54-56].
d. Angiopoietin: is a recently discovered family of growth
factors and angiopoietin1 (Ang1) is expressed in tissue
close to the blood vessels, suggesting a paracrine mode of
action. Angiopoietin 2 (ANG2) is found at sites of tissue
remodeling [57-60].
e. VEGF receptors: In humans, the effect of VEGF on
endothelial cells is mediated via two membrane spanning
receptors, VEGFR1 and VEGFR2. Both receptors have high
affinity for VEGF [61-63]. VEGFR1 Promotes cell migra-
tion, paly a role in organization of blood vessels and gene
expression of monocytes and macrophages. While
VEGFR2 play a major role in mitogenesis, differentiation
of endothelail cells, promotion of cell migration and
enhancement of vascular permeability.
Therapeutic angiogenesis
Therapeutic angiogenesis is the clinical use of methods to
enhance or promote the development of collateral blood
vessels in ischemic tissue. Angiogenic treatment is poten-
tially important as we see more patients that are havingJournal of Cardiothoracic Surgery 2007, 2:49 http://www.cardiothoracicsurgery.org/content/2/1/49
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ischmia or vascular insufficiency that are not amenable to
revascularization. This new form of treatment is an alter-
native to high risk percutaneous coronary intervention or
coronary artery bypass surgery. It can also be used in com-
bination with surgery to provide more complete revascu-
larization.
The ideal agent for therapeutic angiogenesis should have
a potent effect, with sustained clinical benefit [64]. It
should be specific for the targeted ischemic tissue, with no
chronic side effects. It should maintain a high local con-
centration and adequate exposure time. It should be that
the ability of readministration feasible and non invasive
way of delivering the agent should be considered.
There are three major ways to promote angiogenesis: pro-
tein therapy, gene therapy and cellular therapy.
1. Protein therapy
angiogenesis can be achieved by growth factor proteins.
These factors include VEGF, bFGF through different routes
[65]. There are conflicting results reported in the literature
as to the efficacy of these agents [66]. The argument in
favor of protein therapy are Finite temporal exposure to
angiogenic factor, titratable dosing of angiogenic factor
exposure, no exposure to exogenous genetic material, no
exposure to viral vector, readministration may be easier;
decreased risks of inflammatory response or immune
inactivation at the time of repeat dosing, modulation of
protein structure and/or combination with slow- release
delivery system may abrogate issue of protein stability.
The argument against Protein Therapy is that these pro-
teins have short serum half life and so tissue half life and
that would lead to the need of frequent administration
and higher doses.
2. Gene therapy
Gene therapy is known as any manipulation of gene
expression or function for the treatment of specific disease
[66-68]. The advantages of gene therapy are, sustained
production of angiogenic factor resulting in prolonged
exposure to elevated level, the ability for local delivery
and so less systemic exposure. This all can be done with
one dose as well and the production of angiogenic factor
can be directed to specific cell type and so less side effects.
The disadvantages for gene therapy include:
￿ Introduction of foreign genetic material.
￿ Exposure to viral vectors with concomitant risk of
inflammatory response, viral persistence, and in vivo
recombination.
￿ Potential for non- targeted cell gene delivery.
￿ Inability to precisely modulate gene expression and thus
angiogenic factor levels with present vector system.
￿ Potential for inactivation and/or inflammatory response
at readministration.
￿ Potential for long term, low level systemic exposure to
secreted angiogenic factors.
￿ Accelerated atherosclerosis [69,70].
￿ Vascular malformation in the sense of hemangioma for-
mation[71-73]
￿ Neoplasm: there is a raise in concern regarding stimulat-
ing carcinogenesis[41].
￿ Retinopathy [74,75].
￿ Edema: It has been shown that the presence of high
VEGF levels lead to augmentation of vascular permeabil-
ity [76,77].
3. Cellular therapy
this is a new approach in which cells that are known to
produce angiogenic factors are used to promote angiogen-
esis in ischemic tissue [78]. Many cell types have been
used for this purpose as monocytes and endothelial pro-
genator cells and marrow stromal cells. These cells have
been shown to stimulate angiogenesis through expression
of growth factors stimulated by local paracrine stimuli
from ischemia. These cells can also participate as cellular
precursors for vasculogenesis and they can act as a vehicle
for delivery of therapeutic genes coding for angiogenic fac-
tors.
Clinical trials in therapeutic angiogenesis
The results from the preclinical studies about the growing
new blood vessels in the ischemic areas in the heart and
the peripheral parts of the body had led to several clinical
trials which are mainly phase 1 trials investigating the effi-
cacy of different routs of delivery of protein, gene or cellu-
lar therapy.
Few studies were carried out by injecting VEGF protein
through intracoronary and intravenous routs in different
dose scales and showed improvement in symptoms and
in perfusion [79,80]. The problem came with it was the
results were dose dependent and hypotension was quite a
clear complication. The VIVA study was a randomized
double blinded, placebo controlled study that showed no
difference between the two groups in improvement of
symptoms, quality of life And exercise tolerance [81]. TheJournal of Cardiothoracic Surgery 2007, 2:49 http://www.cardiothoracicsurgery.org/content/2/1/49
Page 5 of 7
(page number not for citation purposes)
FGF-2 protein was also studied using intracoronary and
intravenous route in no option patients. Laham et al had
studied in fifty two patients and they received intracoro-
nary protein and there was a significant improvement in
quality of life and exercise time and the infracted defect
size, but the control group was lacking in this study [82].
The FIRST trial was a multicentric randomized double
blinded placebo controlled trial and was designed to
examine the safety, pharmacokinetics and efficacy of FGF-
2 protein but did not show any improvement in exercise
tolerance or myocardial perfusion.
As for the gene therapy, few studies with small numbers of
patients were published till the Angiogenic Gene Therapy
trial (AGENT) with intracoronary infusion of adenovirus
encoding FGF-2. This study stopped enrollment when the
interim analysis showed no possibility of detected effi-
cacy. even though the subgroup analysis with the exercise
tolerance test of less then 10 minutes did show an
improvement [83].
For the cellular therapy, a number of clinical trials for the
endothelial progenitor cells therapy were published in the
last few years. Most of those studies had similar results
which showed a 7–9% improvement in global left ven-
tricular function and remodeling of left ventricle [84].
Other studies for the intramyocardial percutanouse deliv-
ery of autologus bone marrow had shown that this proce-
dure is safe and it improved Angina symptoms and
improve myocardial perfusion and increase left ventricu-
lar function[85-87]. Long term studies are not available.
Conclusion
Therapeutic angiogenesis seems to be the promising hope
for patients with advanced vascular diseases not respond-
ing to the conventional treatment. The different methods
that have been approached in the last two decades keep us
with hope and caution. Couscous measures have to be
taken into consideration in applying any the treatment
options as the unwanted side effects can be prominent.
The present trials in the literature right now do not have
the full answer and more trials will be needed in order to
document these methods as routine alterative methods.
Till then we should stick with our conventional method-
ology whenever it is feasible.
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